Medical management of primary hypertension. 3.
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001593:Benzyl Compounds / Q000627:therapeutic use; D003000:Clonidine / Q000494:pharmacology / Q000627:therapeutic use; D003981:Diazoxide / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D005730:Ganglionic Blockers / Q000009:adverse effects / Q000627:therapeutic use; D006145:Guanethidine / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D006146:Guanidines / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D008517:Phytotherapy; D010946:Plants, Medicinal; D010947:Plants, Toxic; D014703:Veratrum / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D001593:Benzyl Compounds; D005730:Ganglionic Blockers; D006146:Guanidines; D008996:Monoamine Oxidase Inhibitors; D003000:Clonidine; D003981:Diazoxide; D006145:Guanethidine